Primary hyperoxaluria - The German experience

被引:47
作者
Hoppe, B
Latta, K
von Schnakenburg, C
Kemper, MJ
机构
[1] Univ Cologne, Univ Childrens Hosp, Div Pediat Nephrol, D-50931 Cologne, Germany
[2] Clementine Childrens Hosp, Frankfurt, Germany
[3] Univ Childrens Hosp, Div Pediat Nephrol, Freiburg, Germany
[4] Univ Childrens Hosp, Div Pediat Nephrol, Hamburg, Germany
关键词
primary hyperoxaluria; epidemiology; diagnosis; treatment and outcome; oxalate;
D O I
10.1159/000086358
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Primary hyperoxaluria (PH) is a heterogeneous disease with variable age of onset and inconsistent progression into renal failure (ESRF). Aims: In 1994 we initiated a survey within our Pediatric Nephrology working group to ascertain epidemiologic data and current practices. Updates were performed in 2000 and 2004. Results: Diagnosis of PH was made in 65 patients ( 42 with PH type I, 3 with PH type II, 12 unclassified and 8 reported dead), which suggests a minimum prevalence of 0.7 per 1 million of the population. First symptoms were urolithiasis, nephrocalcinosis, urinary tract infection or hematuria. Diagnosis was often delayed and was made only in ESRF in 11% of patients. Measurement of urine metabolites or plasma oxalate in ESRF was performed in 76 and 57%, respectively. Determination of enzyme activity in liver biopsy (55% overall) and mutation analysis have increasingly been performed since 2000 (84.2 and 51%). Treatment included high fluid intake, pyridoxine, citrate and magnesium preparations. Pyridoxine response was reported in 21% of patients. No genotype/ phenotype correlation was seen. Most patients ( 39) do not require renal replacement therapy, 5 patients receive chronic hemodialysis. Preemptive liver (n = 5) and combined liver-kidney transplantation ( n = 9) were the preferred transplantation procedures. Conclusion: Despite increasing knowledge and awareness, diagnosis of PH is still too often delayed and diagnosis only made in ESRF. Most German patients, however, do currently not require renal replacement therapy. Genotype/ phenotype correlations were not found. Combined liver kidney transplantation is the preferred procedure, but has its specific risks. Additional treatment options are clearly needed. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:276 / 281
页数:6
相关论文
共 20 条
[1]  
Amoroso A, 2001, J AM SOC NEPHROL, V12, P2072, DOI 10.1681/ASN.V12102072
[2]   EPIDEMIOLOGY OF PRIMARY HYPEROXALURIA TYPE-1 [J].
COCHAT, P ;
DELORAINE, A ;
ROTILY, M ;
OLIVE, F ;
LIPONSKI, I ;
DERIES, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :3-7
[3]   The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II [J].
Cramer, SD ;
Ferree, PM ;
Lin, K ;
Milliner, DS ;
Holmes, RP .
HUMAN MOLECULAR GENETICS, 1999, 8 (11) :2063-2069
[4]  
DANPURE CJ, 1987, LANCET, V1, P289
[5]   Molecular aetiology of primary hyperoxaluria type 1 [J].
Danpure, CJ .
NEPHRON EXPERIMENTAL NEPHROLOGY, 2004, 98 (02) :E39-E44
[6]   Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure [J].
Hoppe, B ;
Graf, D ;
Offner, G ;
Latta, K ;
Byrd, DJ ;
Michalk, D ;
Brodehl, J .
PEDIATRIC NEPHROLOGY, 1996, 10 (04) :488-492
[7]   A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria [J].
Hoppe, B ;
Langman, CB .
PEDIATRIC NEPHROLOGY, 2003, 18 (10) :986-991
[8]   Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria [J].
Hoppe, B ;
Leumann, E ;
von Unruh, G ;
Laube, N ;
Hesse, A .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2003, 8 :E437-E443
[9]  
HOPPE B, 2004, J AM SOC NEPHROL, V15